摘要:
Disclosed herein are compounds having the following structure useful as inhibitors of carbonic anhydrase IX (CAIX) and XII, and particularly useful for reducing or eliminating metastases see Formula (I).
摘要:
The present document describes methods of use of photoactivated compositions for oral disinfection and/or treatments which comprise at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmacologically acceptable carrier.
摘要:
The compounds have anti-proliferative activity and are useful for treating pathological states and diseases linked to an abnormal cell proliferation such as cancer.
摘要:
The present invention relates to heterocyclic compounds (e.g., compounds described by Formula (I)) and pharmaceutically acceptable salts thereof. The invention also features pharmaceutical compositions that include these compounds and their use in therapy for treating conditions in which necroptosis is likely to play a substantial role. The heterocyclic compounds described herein can also achieve improved activity and selectivity towards RIP1 and/or RIP3.
摘要:
Die vorliegende Erfindung betrifft ein pharmazeutisches Präparat zur Behandlung von Analfissuren, insbesondere zur analen Verabreichung in Zäpfchenform oder als Creme, dadurch gekennzeichnet, dass es zumindest die folgenden Bestandteile umfasst: a. Papaverin oder ein Papaverinderivat b. Alpha-Bisabolol c. Allantoin d. Prednisolon.
摘要:
This invention is directed to a topical cream containing allantoin in an oil-in-water emulsion formulation. A method is provided for treating or reducing keloid formation in a patient in need thereof comprising contacting the patient's skin with an effective amount of a composition comprising allantoin in an amount from about 3.0% to about 15% by weight and a pharmaceutically acceptable excipient. In contrast to other efforts to reduce keloid formation, the present invention uses topical compositions comprising allantoin as an active pharmaceutical ingredient at higher concentrations and reduces or eliminates the occurrence of keloid formation in a shorter period of time after using the topical composition comprising allantoin.